Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer survivors may carry hidden aging markers that raise disease risk

NCT ID NCT07114614

Knowledge-focused Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 4 times

Summary

This study will compare levels of fatty acid binding proteins and cellular aging markers in 120 cancer survivors versus people who never had cancer. Researchers want to see if these markers are higher in survivors and linked to conditions like diabetes and high blood pressure. Participants will provide blood samples, and no treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify biomarkers that predict chronic disease risk in cancer survivors, potentially guiding future preventive care.
What could go wrong
This is an observational study with no treatment being tested. It is early-stage research, and findings may not lead to direct clinical changes or apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For pediatric control participants, labs will be drawn with IV placement prior to procedure or sedation. Measurements will be taken during the same visit. If desired by patient and parent, a separate research visit can be arranged for participants to have labs drawn at their convenience. For adult control participants, a research visit will be arranged at the participants' convenience for measurements to be obtained and study labs to be drawn.

Ages

5 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of at least one malignancy for which chemotherapy, radiation, and/or stem cell transplantation was utilized as part of treatment * Completed all therapeutic interventions for their malignancy and are at least 2 years off therapy * At least 1-year post-stem cell transplant for malignant condition Exclusion Criteria: 1. Pregnancy at the time of the study 2. Any autoimmune condition including but not limited to lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, EXCEPT well-controlled autoimmune hypothyroidism for at least 6 months 3. Presence of active graft versus host disease 4. Malignancy treated using surgery only 5. Acute relapsed disease or second malignancy 6. Transplant for non-malignant conditions (e.g. cell disease, Hurler syndrome) 7. Currently taking systemic steroids and/or immunosuppressant medications 8. Acute illness necessitating hospitalization in the 30 days prior to blood draw 9. Presence of a chronic inflammatory disease EXCEPT obesity 10. Fever, active infection or inflammation, or taking antibiotics at the time of blood draw 11. A diagnosis of Type 2 diabetes or Hypertension treated with medication 12. Currently lipid lowering medications 13. Growth hormone deficiency or hypothalamic dysfunction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer structural epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Marker; structural

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Case Comprehensive Cancer Center, UH Rainbow Babies & Children's Hospital

    RECRUITING

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.